Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
MYCN is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. De plus, nous expédions MYCN Protéines (7) et MYCN Kits (6) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 98 products:
Human Monoclonal MYCN Primary Antibody pour ChIP, CyTOF - ABIN152254
Tasseva, Cole, Vance: N-Myc and SP regulate phosphatidylserine synthase-1 expression in brain and glial cells. dans The Journal of biological chemistry 2011
Show all 3 Pubmed References
Mouse (Murine) Polyclonal MYCN Primary Antibody pour ICC, IF - ABIN256650
Sjostrom, Finn, Hahn, Rowitch, Kenney: The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. dans Developmental cell 2005
Show all 2 Pubmed References
Human Polyclonal MYCN Primary Antibody pour WB - ABIN391590
Li, Sun, Chen, Squires, Nowroozizadeh, Liang, Huang: p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. dans Molecular cancer research : MCR 2015
Human Polyclonal MYCN Primary Antibody pour IF (p), IHC (p) - ABIN760676
Ramraj, Aravindan, Somasundaram, Herman, Natarajan, Aravindan: Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease. dans Oncotarget 2016
PRMT1 (Montrer PRMT1 Anticorps) has a role in regulating MYCN in neuroblastoma (Montrer ARHGEF16 Anticorps)
N-myc levels appear to be modulated by the antagonistic interactions of both miR-17, as a negative regulator, and HuD (Montrer ELAVL4 Anticorps), as a positive regulator in N-myc-amplified neuroblastoma (Montrer ARHGEF16 Anticorps) cells.
We also propose a model for the stabilization mechanism in which binding to Aurora-A (Montrer AURKA Anticorps) alters how N-Myc interacts with SCF (Montrer KITLG Anticorps)(FbxW7 (Montrer FBXW7 Anticorps)) to disfavor the generation of Lys48-linked polyubiquitin (Montrer UBB Anticorps) chains
This study provides a novel insight for miR (Montrer MLXIP Anticorps)-221 in the control of neuroblastoma (Montrer ARHGEF16 Anticorps) cell proliferation and tumorigenesis, suggesting potentials of miR (Montrer MLXIP Anticorps)-221 as a prognosis marker and therapeutic target for patients with MYCN overexpressing neuroblastoma (Montrer ARHGEF16 Anticorps).
N-MYC is in the downstream-regulated gene family in reprogramming cancer metabolism under hypoxia [review]
SNHG1 is up-regulated by MYCN amplification and could be a potential prognostic biomarker for high-risk neuroblastoma (Montrer ARHGEF16 Anticorps) intervention.
MYCN expression is a marker indicative of likely clinical sensitivity to mTOR (Montrer FRAP1 Anticorps) inhibition in neuroblastoma (Montrer ARHGEF16 Anticorps) cells
Results show that MYCN and LSD1 (Montrer KDM1A Anticorps) co-localize at NDRG1 (Montrer NDRG1 Anticorps) promoter and repress its expression in neuroblastoma (Montrer ARHGEF16 Anticorps) cells.
Data indicate cross-talks between MYCN and beta-catenin (Montrer CTNNB1 Anticorps) signalling, which repress normal beta-catenin (Montrer CTNNB1 Anticorps) mediated transcriptional regulation.
Data show that transcription factor activating enhancer binding protein-4 (TFAP4) is a direct transcriptional target of MYCN in neuroblastoma (Montrer ARHGEF16 Anticorps) and that high levels of this transcription factor are associated with poor clinical outcome in this disease.
interactions of NF-kappaB (Montrer NFKB1 Anticorps) and N-myc with GLT-1/EAAT2 (Montrer SLC1A2 Anticorps) promoter sequences was significantly elevated in the ipsi-lateral cortex of both adult and old Traumatic brain injury mice.
beta-catenin (Montrer CTNNB1 Anticorps) cooperates with the transcription factor Myc (Montrer MYC Anticorps) to activate the progenitor renewal program.
we report the isolation and propagation of neuroblastoma (Montrer ARHGEF16 Anticorps) sphere-forming cells with self-renewal and differentiation potential from tumors of the TH-MYCN mouse, an animal model of high-risk neuroblastoma (Montrer ARHGEF16 Anticorps) with MYCN amplification
miR (Montrer MLXIP Anticorps)-34a contributes to the expansion of Myeloid-derived suppressor cells by inhibiting the apoptosis via suppressing the expression of N-myc.
the role of N-myc in mouse lens development, was examined.
Using comparative genomic hybridization, authors found that NCC (Montrer SLC12A3 Anticorps)-derived NBL (Montrer NUMBL Anticorps) tumors in mice acquired copy number gains and losses that are syntenic to those observed in human MYCN-amplified NBL (Montrer NUMBL Anticorps) including 17q gain, 2p gain and loss of 1p36.
a Mycn target gene encoding the miR (Montrer MLXIP Anticorps) cluster miR-17~92, while most retinoblastomas reemerged without clear genetic alterations in either Mycn or known Mycn targets. This Rb/MYCN model recapitulates key genetic driver alterations seen in human retinoblastoma and reveals the emergence of MYCN independence in an initially MYCN-driven tumor.
The findings reveal a PLK1 (Montrer PLK1 Anticorps)-Fbw7 (Montrer FBXW7 Anticorps)-Myc (Montrer MYC Anticorps) signaling circuit that underlies tumorigenesis and validate PLK1 (Montrer PLK1 Anticorps) inhibitors, alone or with Bcl2 (Montrer BCL2 Anticorps) antagonists, as potential effective therapeutics for MYC (Montrer MYC Anticorps)-overexpressing cancers.
ALKR1275Q cooperated with MYCN in the development of aggressive NB, possibly by downregulating the expression of ECM (Montrer MMRN1 Anticorps)/BM-associated genes and by conferring malignant potentials to MYCN-expressing cells.
Reuslts show that N-Myc overexpression leads to the development of poorly differentiated, invasive prostate cancer that is molecularly similar to human NEPC.
In MYCN transgenic fish, Gab2 (Montrer GAB2 Anticorps) overexpression activated the Shp2 (Montrer PTPN11 Anticorps)-Ras (Montrer RAB1A Anticorps)-Erk (Montrer MAPK1 Anticorps) pathway, enhanced neuroblastoma (Montrer ARHGEF16 Anticorps) induction, and increased tumor penetrance.
The authors demonstrate in zebrafish that nf1 (Montrer NF1 Anticorps) loss leads to aberrant activation of RAS (Montrer RAB1A Anticorps) signaling in MYCN-induced neuroblastomas that arise in these precursors, and that the GTPase-activating protein (GAP)-related domain (GRD) is sufficient to suppress the acceleration of neuroblastoma (Montrer ARHGEF16 Anticorps) in nf1 (Montrer NF1 Anticorps)-deficient fish, but not the hypertrophy of sympathoadrenal cells in nf1 (Montrer NF1 Anticorps) mutant embryos.
At somitogenesis stages, nmyc1 expression was detected in the retina, midbrain, posterior hindbrain and presumptive spinal cord. It was also transcribed in the endoderm and its derivatives as well as in branchial arches.
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.
N-myc proto-oncogene protein
, class E basic helix-loop-helix protein 37
, neuroblastoma MYC oncogene
, neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene
, oncogene NMYC
, v-myc avian myelocytomatosis viral related oncogene, neuroblastoma derived
, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
, N-myc protein
, neuroblastoma myc-related oncogene 1
, Avian myelocytomatosis viral (v-myc) related oncogene neuroblastoma derived (Nmyc)
, Avian myelocytomatosis viral (v-myc) related oncogene, neuroblastoma derived (Nmyc)
, N-myc-like protein
, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
, MYCN proto-oncogene, bHLH transcription factor S homeolog
, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog S homeolog
, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived, a